2 studies test drug used to treat ovarian cancer

December 28, 2011 1:46:53 PM PST
Results in the New England Journal of Medicine found Avastin did not improve survival for most of these patients. It also kept their disease from worsening for only a few months with more side effects.

The Genentech drug won approval in Europe last week for advanced ovarian cancer. But its maker has no immediate plans to seek the same approval in the United States.

In November, the FDA revoked Avastin's approval for breast cancer. It can still be sold for colon, lung, kidney and brain cancers. The new research was aimed at adding ovarian cancer to the list.